Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report

Research output: Contribution to journal › Comment/debate › Research

Standard

Clinical development of placental malaria vaccines and immunoassays harmonization : a workshop report. / Chêne, Arnaud; Houard, Sophie; Nielsen, Morten A; Hundt, Sophia; D'Alessio, Flavia; Sirima, Sodiomon B; Luty, Adrian J F; Duffy, Patrick; Leroy, Odile; Gamain, Benoit; Viebig, Nicola K.

In: Malaria Journal, Vol. 15, 476, 17.09.2016.

Research output: Contribution to journal › Comment/debate › Research

Harvard

Chêne, A, Houard, S, Nielsen, MA, Hundt, S, D'Alessio, F, Sirima, SB, Luty, AJF, Duffy, P, Leroy, O, Gamain, B & Viebig, NK 2016, 'Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report', Malaria Journal, vol. 15, 476. https://doi.org/10.1186/s12936-016-1527-8

APA

Chêne, A., Houard, S., Nielsen, M. A., Hundt, S., D'Alessio, F., Sirima, S. B., Luty, A. J. F., Duffy, P., Leroy, O., Gamain, B., & Viebig, N. K. (2016). Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. Malaria Journal, 15, [476]. https://doi.org/10.1186/s12936-016-1527-8

Vancouver

Chêne A, Houard S, Nielsen MA, Hundt S, D'Alessio F, Sirima SB et al. Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. Malaria Journal. 2016 Sep 17;15. 476. https://doi.org/10.1186/s12936-016-1527-8

Author

Chêne, Arnaud ; Houard, Sophie ; Nielsen, Morten A ; Hundt, Sophia ; D'Alessio, Flavia ; Sirima, Sodiomon B ; Luty, Adrian J F ; Duffy, Patrick ; Leroy, Odile ; Gamain, Benoit ; Viebig, Nicola K. / Clinical development of placental malaria vaccines and immunoassays harmonization : a workshop report. In: Malaria Journal. 2016 ; Vol. 15.

Bibtex

@article{fed51a8f2cc54ef28f3d6ecfaee56d86,
title = "Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report",
abstract = "Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Prevention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resistance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. A placental malaria vaccine would be an attractive, cost-effective complement to the existing control tools. Two placental malaria vaccine candidates are currently in Phase Ia/b clinical trials. During two workshops hosted by the European Vaccine Initiative, one in Paris in April 2014 and the other in Brussels in November 2014, the main actors in placental malaria vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to define standards that will allow comparative assessment of different placental malaria vaccine candidates. The recommendations of these workshops should guide researchers and clinicians in the further development of placental malaria vaccines.",
author = "Arnaud Ch{\^e}ne and Sophie Houard and Nielsen, {Morten A} and Sophia Hundt and Flavia D'Alessio and Sirima, {Sodiomon B} and Luty, {Adrian J F} and Patrick Duffy and Odile Leroy and Benoit Gamain and Viebig, {Nicola K}",
year = "2016",
month = sep,
day = "17",
doi = "10.1186/s12936-016-1527-8",
language = "English",
volume = "15",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",

}

RIS

TY - JOUR

T1 - Clinical development of placental malaria vaccines and immunoassays harmonization

T2 - a workshop report

AU - Chêne, Arnaud

AU - Houard, Sophie

AU - Nielsen, Morten A

AU - Hundt, Sophia

AU - D'Alessio, Flavia

AU - Sirima, Sodiomon B

AU - Luty, Adrian J F

AU - Duffy, Patrick

AU - Leroy, Odile

AU - Gamain, Benoit

AU - Viebig, Nicola K

PY - 2016/9/17

Y1 - 2016/9/17

N2 - Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Prevention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resistance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. A placental malaria vaccine would be an attractive, cost-effective complement to the existing control tools. Two placental malaria vaccine candidates are currently in Phase Ia/b clinical trials. During two workshops hosted by the European Vaccine Initiative, one in Paris in April 2014 and the other in Brussels in November 2014, the main actors in placental malaria vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to define standards that will allow comparative assessment of different placental malaria vaccine candidates. The recommendations of these workshops should guide researchers and clinicians in the further development of placental malaria vaccines.

AB - Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Prevention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resistance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. A placental malaria vaccine would be an attractive, cost-effective complement to the existing control tools. Two placental malaria vaccine candidates are currently in Phase Ia/b clinical trials. During two workshops hosted by the European Vaccine Initiative, one in Paris in April 2014 and the other in Brussels in November 2014, the main actors in placental malaria vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to define standards that will allow comparative assessment of different placental malaria vaccine candidates. The recommendations of these workshops should guide researchers and clinicians in the further development of placental malaria vaccines.

U2 - 10.1186/s12936-016-1527-8

DO - 10.1186/s12936-016-1527-8

M3 - Comment/debate

C2 - 27639691

VL - 15

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

M1 - 476

ER -

ID: 165895238